HONGKONG, 6. Dezember 2025 /PRNewswire/ — LiberNovo, ein führendes Unternehmen im Bereich der Arbeitsplatzinnovation, ist nun offiziell in Europa vertreten und bietet weltweit das gesamte Sortiment des LiberNovo Omni an – dem dynamischen ergonomischen Bürostuhl der nächsten Generation, der sich jeder kleinsten Bewegung des Körpers anpasst. Mit integrierter Auftragsabwicklung in den USA, Kanada, der EU, Deutschland… Continue reading LiberNovo kommt mit Omni nach Europa – dem ergonomischen Stuhl der nächsten Generation, den Sie jetzt bestellen können
Author: PR Newswire Online News
LiberNovo débarque en Europe avec Omni – la chaise ergonomique de nouvelle génération que vous pouvez commander dès maintenant
HONG KONG, 6 décembre 2025 /PRNewswire/ — LiberNovo, leader de l’innovation dans les environnements de travail, a officiellement lancé ses activités en Europe, avec une disponibilité mondiale complète des stocks pour le LiberNovo Omni – le siège de bureau ergonomique dynamique de nouvelle génération conçu pour s’adapter à tous les micro-mouvements du corps. Avec une gestion… Continue reading LiberNovo débarque en Europe avec Omni – la chaise ergonomique de nouvelle génération que vous pouvez commander dès maintenant
LiberNovo Lands in Europe with Omni — The Next-Gen Ergonomic Chair You Can Order Now
HONG KONG, Dec. 6, 2025 /PRNewswire/ — LiberNovo, a leader in workspace innovation, has officially launched in Europe with full global inventory availability for the LiberNovo Omni — the next-generation dynamic ergonomic office chair designed to adapt to every micro-movement of the body. With integrated fulfillment across the US, Canada, the EU, Germany, and the UK,… Continue reading LiberNovo Lands in Europe with Omni — The Next-Gen Ergonomic Chair You Can Order Now
LiberNovo llega a Europa con Omni, la silla ergonómica de nueva generación que puedes pedir ahora
HONG KONG, 6 de diciembre de 2025 /PRNewswire/ — LiberNovo, líder en innovación en espacios de trabajo, ha lanzado oficialmente en Europa, con disponibilidad total en todo el mundo, la LiberNovo Omni, la silla de oficina ergonómica y dinámica de última generación, diseñada para adaptarse a cada micromovimiento del cuerpo. Con un sistema de gestión… Continue reading LiberNovo llega a Europa con Omni, la silla ergonómica de nueva generación que puedes pedir ahora
LiberNovo Goes Global: New Markets & A Vision for Healthy Workspaces
HONG KONG, Dec. 6, 2025 /PRNewswire/ — For the millions of programmers, creative professionals, and remote workers battling the inertia of sedentary work, a breakthrough moment has arrived. LiberNovo, the company pioneering the next generation of workspace solutions, today announced the global, full-inventory launch of the LiberNovo Omni – the world’s first dynamic ergonomic office… Continue reading LiberNovo Goes Global: New Markets & A Vision for Healthy Workspaces
FLY Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of January 12, 2026 Deadline in Securities Fraud Class Action Lawsuit Against Firefly Aerospace Inc. (FLY)
RADNOR, Pa., Dec. 6, 2025 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Firefly Aerospace Inc. (“Firefly”) (NASDAQ: FLY) on behalf of those who purchased or otherwise acquired Firefly: (1) common stock pursuant and/or traceable to the registration statement and… Continue reading FLY Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of January 12, 2026 Deadline in Securities Fraud Class Action Lawsuit Against Firefly Aerospace Inc. (FLY)
Blokees exhibits at CCXP25 in Brazil: World Premiere of the New Saint Seiya Product
SHANGHAI, Dec. 6, 2025 /PRNewswire/ — From December 4 to 7, Assembly Character Toys brand Blokees made its first debut at Brazil Comic Con Experience (CCXP). Blokees exhibited its two major categories “Blokees Model Kits” and “BLOKEES WHEELS”, with nearly 60 products based on over 10 world-renowned IPs including Transformers, Jurassic World, Saint Seiya, EVANGELION.… Continue reading Blokees exhibits at CCXP25 in Brazil: World Premiere of the New Saint Seiya Product
SFM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sprouts Farmers Market, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, Dec. 6, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers of Sprouts Farmers Market, Inc. (NASDAQ: SFM) securities between June 4, 2025 and October 29, 2025, both dates inclusive (the “Class Period”), including sellers of put options, have until January 26, 2026 to seek appointment as lead plaintiff of the… Continue reading SFM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sprouts Farmers Market, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin’s Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ — Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang,… Continue reading Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin’s Lymphoma at the 2025 ASH Annual Meeting
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line Data suggest stronger immune fitness in earlier lines may be associated with longer progression free survival ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) announced today… Continue reading Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma